Is NSAIDs-related gastrointestinal damage preventable?

Journal of Digestive Diseases

Volumn 14, Issue 2, 2013, Pages 55-61

  Gargallo, Carla J ^a   Lanas, Angel ^a,b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anti inflammatory agent; Gastrointestinal tract; Hemorrhage; Non steroidal; Preventive strategy

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; FAMOTIDINE; IBUPROFEN; INDOMETACIN; KETOROLAC; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PROSTAGLANDIN; PROTON PUMP INHIBITOR; REBAMIPIDE; RIFAXIMIN; ROFECOXIB;

ABDOMINAL PAIN; ARTICLE; ATROPHIC GASTRITIS; CARDIOVASCULAR DISEASE; CLOSTRIDIUM INFECTION; COLON ULCER; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG HALF LIFE; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; INTESTINE ULCER; LOW DRUG DOSE; MALABSORPTION; NAUSEA; OSTEOPOROSIS; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ULCER; SUSTAINED DRUG RELEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; MISOPROSTOL; PROSTAGLANDINS; PROTON PUMP INHIBITORS;

EID: 84873054712     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12019     Document Type: Article

References (57)

1. Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-1378.
2. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
3. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099.
4. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.
5. Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010; 77: 6-12.
6. Lanas A, Rodríguez LA, Carrera P etal. Helicobacter pylori infection and the risk of upper GI bleeding in patients taking NSAIDs or aspirin. Gastroenterology 2012; 142: S104.
7. Hawkey CJ, Tulassay Z, Szczepanski L etal. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021.
8. Chan FK, Sung JJ, Chung SC etal. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
9. Chan FK, To KF, Wu JC etal. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
10. Lanas A, García-Rodríguez LA, Arroyo MT etal; Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
11. Castellsague J, Riera-Guardia N, Calingaert B etal; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127-1146.
12. Rostom A, Muir K, Dubé C etal. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-828, 828.e1-5; quiz 768.
13. Silverstein FE, Faich G, Goldstein JL etal. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-1255.
14. Schnitzer TJ, Burmester GR, Mysler E etal.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674.
15. Singh G, Fort JG, Goldstein JL etal.; SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119: 255-266.
16. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47-71.
17. Trelle S, Reichenbach S, Wandel S etal. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
18. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PloS Med 2011; 8: e1001098.
19. Rostom A, Wells G, Tugwell P, Welch V, Dubé C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27: 2203-2214.
20. Leontiadis GI, Sreedharan A, Dorward S etal. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11: iii-iv, 1-164.
21. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948.
22. Pérez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21: 65-72.
23. Lin KJ, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011; 141: 71-79.
24. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615-620.
25. Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr 2008; 42: 71-75.
26. Ho PM, Maddox TM, Wang L etal. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
27. Juurlink DN, Gomes T, Ko DT etal. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
28. O'Donoghue ML, Braunwald E, Antman EM etal. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
29. Depta JP, Bhatt DL. Omeprazole and clopidogrel: Should clinicians be worried? Cleve Clin J Med 2010; 77: 113-116.
30. Bhatt DL, Cryer BL, Contant CF etal, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
31. Chan FK, Hung LC, Suen BY etal. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-2110.
32. Chan FK, Chung SC, Suen BY etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973.
33. Chan FK, Wong VW, Suen BY etal. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626.
34. Lanas A, García-Rodríguez LA, Polo-Tomás M etal. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-1641.
35. Bjarnason I, Zanelli G, Prouse P etal. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; 2: 711-714.
36. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-754.
37. Kurahara K, Matsumoto T, Iida M, Honda K, Yao T, Fujishima M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol 2001; 96: 473-480.
38. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-869.
39. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-767.
40. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-473.
41. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32: 275-277.
42. Smecuol E, Bai JC, Sugai E etal. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001; 49: 650-655.
43. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141.
44. Goldstein JL, Eisen GM, Lewis B etal. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 1211-1222.
45. Yoda Y, Amagase K, Kato S etal. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 2010; 61: 287-294.
46. Fujimori S, Seo T, Gudis K etal. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009; 69: 1339-1346.
47. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993; 38: 417-425.
48. Niwa Y, Nakamura M, Ohmiya N etal. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008; 43: 270-276.
49. Maiden L, Thjodleifsson B, Seigal A etal. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040-1045.
50. Sugimori S, Watanabe T, Tabuchi M etal. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008; 78: 208-213.
51. Laine L, Connors LG, Reicin A etal. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-292.
52. Laine L, Curtis SP, Langman M etal. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517-1525.
53. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
54. Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 2008; 57: 145-148.
55. Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006; 73 Suppl 1: 136-150.
56. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-1208.
57. 2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem 2011; 18: 3494-3505.